Javascript must be enabled to continue!
Efficacy and Safety Meta-analysis of Whether Denervation Is Combined With Pulmonary Vein Isolation in the Treatment of Hypertension Combined With Atrial Fibrillation
View through CrossRef
Abstract
OBJECTIVE
To evaluate the effectiveness of denervation sympathectomy (RDN) and pulmonary vein isolation (PVI) for the treatment of hypertension combined with atrial fibrillation (AF) and to examine the safety of the combined procedure.
METHODS
Computerized retrieval of clinical research papers concerning PVI combined with RDN for the treatment of patients with hypertension and AF from the databases of Pubmed, Cochrane Library, EMbase, Web of Science, Chinese Academic Journals (CNKI), and Wanfang documented in the period from January 2010 to April 2023 was conducted. Revman 5.3 software and Stata15.1 were used to make meta-analysis.
RESULTS
A total of 10 papers including 859 patients were enrolled in this study. Meta-analysis showed that 12 months after treatment the recurrence risk of AF was significantly lower in the RDN combined with PVI group compared with the PVI group (RR: 0.61, 95% confidence interval [CI] 0.51 to 0.73, P < 0.01), but pooled analysis showed no difference in AF recurrence rate at 24 months (RR: 0.96, 95% CI 0.63 to 1.45, P = 0.84). The postoperative AF recurrence rate was significantly reduced in the RDN combined with PVI group in patients with paroxysmal AF and refractory hypertension (RR: 0.64, 95% CI 0.51 to 0.81, P < 0.01; RR: 0.70, 95% CI 0.56 to 0.88, P < 0.01). Pooled analysis of patients showed a significant mean reduction of systolic blood pressure (WMD: −6.20 mm Hg, 95% CI −10.79 to −1.62, P < 0.01), septum, left ventricular end-diastolic internal diameter, and left ventricular mass index compared to PVI alone (WMD: −1.25 mm, 95% CI −1.57 to −0.93, P < 0.01; WMD: −2.37 mm, 95% CI −4.63 to −0.11, P = 0.04; WMD: −14.59 g/m2, 95% CI −18.06 to −11.11, P < 0.01); but not diastolic blood pressure (WMD: −3.19 mm Hg, 95% CI −6.81 to 0.44, P = 0.08). Additionally, the pooled analysis showed that PVI + RDN significantly improved estimated glomerular filtration rate (WMD: 14.79 ml/(min·1.73 m2), 95% CI 12.95 to 16.63), reduced creatinine (WMD: −0.27 mg/dl, 95% CI −0.36 to −0.18, P < 0.01), and urinary albumin/urinary creatinine compared to PVI alone (WMD: −50.26, 95% CI −77.01 to −23.52, P < 0.01). In terms of safety, the complication rate was not statistically significant in both groups (1.46, 95% CI 0.75 to 2.83, P = 0.26).
CONCLUSIONS
RDN combined with PVI surgery can reduce the recurrence rate of AF at 12 months in hypertensive patients with AF, but could not improve the recurrence rate at 24 months after surgery, and the combined surgery has better efficacy and safety.
Oxford University Press (OUP)
Title: Efficacy and Safety Meta-analysis of Whether Denervation Is Combined With Pulmonary Vein Isolation in the Treatment of Hypertension Combined With Atrial Fibrillation
Description:
Abstract
OBJECTIVE
To evaluate the effectiveness of denervation sympathectomy (RDN) and pulmonary vein isolation (PVI) for the treatment of hypertension combined with atrial fibrillation (AF) and to examine the safety of the combined procedure.
METHODS
Computerized retrieval of clinical research papers concerning PVI combined with RDN for the treatment of patients with hypertension and AF from the databases of Pubmed, Cochrane Library, EMbase, Web of Science, Chinese Academic Journals (CNKI), and Wanfang documented in the period from January 2010 to April 2023 was conducted.
Revman 5.
3 software and Stata15.
1 were used to make meta-analysis.
RESULTS
A total of 10 papers including 859 patients were enrolled in this study.
Meta-analysis showed that 12 months after treatment the recurrence risk of AF was significantly lower in the RDN combined with PVI group compared with the PVI group (RR: 0.
61, 95% confidence interval [CI] 0.
51 to 0.
73, P < 0.
01), but pooled analysis showed no difference in AF recurrence rate at 24 months (RR: 0.
96, 95% CI 0.
63 to 1.
45, P = 0.
84).
The postoperative AF recurrence rate was significantly reduced in the RDN combined with PVI group in patients with paroxysmal AF and refractory hypertension (RR: 0.
64, 95% CI 0.
51 to 0.
81, P < 0.
01; RR: 0.
70, 95% CI 0.
56 to 0.
88, P < 0.
01).
Pooled analysis of patients showed a significant mean reduction of systolic blood pressure (WMD: −6.
20 mm Hg, 95% CI −10.
79 to −1.
62, P < 0.
01), septum, left ventricular end-diastolic internal diameter, and left ventricular mass index compared to PVI alone (WMD: −1.
25 mm, 95% CI −1.
57 to −0.
93, P < 0.
01; WMD: −2.
37 mm, 95% CI −4.
63 to −0.
11, P = 0.
04; WMD: −14.
59 g/m2, 95% CI −18.
06 to −11.
11, P < 0.
01); but not diastolic blood pressure (WMD: −3.
19 mm Hg, 95% CI −6.
81 to 0.
44, P = 0.
08).
Additionally, the pooled analysis showed that PVI + RDN significantly improved estimated glomerular filtration rate (WMD: 14.
79 ml/(min·1.
73 m2), 95% CI 12.
95 to 16.
63), reduced creatinine (WMD: −0.
27 mg/dl, 95% CI −0.
36 to −0.
18, P < 0.
01), and urinary albumin/urinary creatinine compared to PVI alone (WMD: −50.
26, 95% CI −77.
01 to −23.
52, P < 0.
01).
In terms of safety, the complication rate was not statistically significant in both groups (1.
46, 95% CI 0.
75 to 2.
83, P = 0.
26).
CONCLUSIONS
RDN combined with PVI surgery can reduce the recurrence rate of AF at 12 months in hypertensive patients with AF, but could not improve the recurrence rate at 24 months after surgery, and the combined surgery has better efficacy and safety.
Related Results
Multimodality imaging of chronic thromboembolic pulmonary hypertension : new insights into old challenges
Multimodality imaging of chronic thromboembolic pulmonary hypertension : new insights into old challenges
<p dir="ltr"><b>BACKGROUND:</b><br><br>Most forms of pulmonary hypertension carry unsatisfactory prognosis with the notable exception of chronic throm...
Multimodality imaging of chronic thromboembolic pulmonary hypertension : new insights into old challenges
Multimodality imaging of chronic thromboembolic pulmonary hypertension : new insights into old challenges
<p dir="ltr"><b>BACKGROUND:</b><br><br>Most forms of pulmonary hypertension carry unsatisfactory prognosis with the notable exception of chronic throm...
Adiponectin and Lone atrial fibrillation
Adiponectin and Lone atrial fibrillation
Objective: Lone atrial fibrillation is an idiopathic arrhythmia seen in younger individuals without any secondary disease. Adiponectin is an endogenous adipocytokine that increases...
P1415Wide antral circumferential pulmonary vein isolation ablation using a novel balloon cryoablation catheter
P1415Wide antral circumferential pulmonary vein isolation ablation using a novel balloon cryoablation catheter
Abstract
Background
Pulmonary vein isolation using cryotherapy is an established treatment for the management of patients with p...
RELATIONSHIP BETWEEN ATRIAL FIBRILLATION CARDIOVERSION AND F
RELATIONSHIP BETWEEN ATRIAL FIBRILLATION CARDIOVERSION AND F
Objectives
To investigate the relationship between atrial fibrillation cardioversion and f wave in electrocardiogram, providing an ordinary and noninvasive method...
ASSA13-03-9 Decreased Expression of Small-Conductance Ca2+-Activated K+ Channels SK1, SK2, and SK3 in Patients with Persistent Atrial Fibrillation
ASSA13-03-9 Decreased Expression of Small-Conductance Ca2+-Activated K+ Channels SK1, SK2, and SK3 in Patients with Persistent Atrial Fibrillation
Background
Small-conductance Ca2+-activated K+ channels (SK channels) have been reported involved in atrial fibrillation (AF) as a new ion channel candidates, as ...
Diagnostic accuracy of an oscillometric blood pressure monitor for atrial fibrillation screening
Diagnostic accuracy of an oscillometric blood pressure monitor for atrial fibrillation screening
Objective
Atrial fibrillation is the most common arrhythmia of clinical significance and hypertension is one of its major risk factors. This study aimed to evaluate the...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...

